Atomera’s Revenue Jumps 9x, But Losses Persist

Forward-Looking Analysis

Atomera is projected to report modest revenue growth for the second quarter of 2026, with estimates indicating a rise to approximately $100,000. This figure represents a significant increase from the previous quarter’s reported revenue of $11,000. Despite this top-line improvement, profitability challenges persist. Analysts forecast an earnings per share (EPS) of -$0.13 for the period. This estimate marks a slight improvement from the last quarter’s actual EPS of -$0.17, though it reflects a miss against earlier consensus expectations that had predicted a loss of -$0.13. The company’s net income is expected to remain deeply negative, continuing the trend of substantial quarterly losses. The divergence between the estimated EPS of -$0.13 and the actual result of -$0.17 in the prior quarter highlights the volatility in Atomera’s financial performance. Wall Street coverage remains limited, with no recent analyst upgrades or downgrades available in the provided data. The market capitalization of approximately $103.89 million places Atomera in the micro-cap category, where liquidity and earnings predictability can be more volatile. Investors should anticipate a narrow margin of error regarding revenue recognition, as the company continues its early-stage commercialization efforts for its Mears Silicon Technology (MST). The focus remains on whether the projected $100,000 in revenue can begin to offset the persistent operating losses that have defined the company’s recent financial history.

Historical Performance Review

Atomera’s 2026Q1 results demonstrated continued operational struggles with minimal revenue generation. The company reported total revenue of just $11.00 thousand, reflecting a severe contraction in commercial activity. Net income stood at $-6.07 million, indicating a substantial loss that widened the deficit compared to prior periods. Earnings per share were recorded at $-0.17, consistent with the high burn rate. Gross profit was negative $115.00 thousand, underscoring the fact that operating costs significantly outpaced any marginal gains from sales. These figures highlight the company's ongoing reliance on external financing to sustain operations while navigating the long development cycle of its semiconductor technology licensing model.

Additional News

Atomera has advanced its Mears Silicon Technology (MST) for RF GaN-on-Silicon applications, with a concept moving to the proposal phase in the Power America funding program. The company extended its collaboration with Synopsys to accelerate GaN modeling for high-value RF and power devices. Technically, Atomera achieved a manufacturability breakthrough of MST on Gate-All-Around (GAA) transistors. Commercially, a top-20 customer began running GaN wafers with MST. Leadership changes include the appointment of Nishant Sinha as Head of Marketing in February 2026 to drive strategy and customer development. Earlier, Wei Na was hired as Vice President of Sales to accelerate commercial growth. Financially, Atomera closed a $25 million registered direct offering in February 2026, raising approximately $23.6 million in net proceeds to support working capital. These developments signal a strategic push to deepen industry partnerships and secure funding amid ongoing operational losses.

Summary & Outlook

Atomera’s financial health remains precarious, characterized by negligible revenue and persistent net losses. The transition from $11k to an estimated $100k in Q2 2026 revenue is positive but insufficient to offset the $-0.13 EPS and deep negative net income. Growth catalysts include the MST breakthroughs in GAA transistors and RF GaN-on-Silicon, alongside strategic hires and a recent $25M capital raise. However, the company’s inability to generate gross profit ($-115k in Q1) and the absence of sustained licensing revenue present significant risks. While the technology shows promise, the path to profitability is distant. The outlook is bearish due to the high cash burn relative to minuscule sales, though the recent capital infusion provides short-term runway. Investors face high risk with limited near-term financial rewards.